Compare Ecolab Inc. (ECL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Pfizer Inc — how do they compare? Ecolab Inc. trades at $273.17 (market cap $76.06B), while Pfizer Inc trades at $25.1 (market cap $141.46B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| ECL | PFE | |
|---|---|---|
Market Cap | $76.06B | $141.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $28.56 |
52-Week Low | $245.73 | $23.29 |
Enterprise Value | $84.81B | $192.12B |
Dividend Yield | 1.08% | 6.93% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $273.62, up 1.43% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with $16.08B revenue, 12.8% net margin, and 22.31% ROE. Recent Q1 2026 earnings met expectations while Q2 2026 results are pending. The $4.75B CoolIT acquisition strengthens AI cooling capabilities, positioning for long-term growth in high-tech markets.
ECL presents a compelling growth story with improving profitability and strategic acquisitions, though current valuation multiples appear elevated. Key risks include execution of recent acquisitions and rising cost pressures. With 76% analyst buy ratings and a $327.43 consensus target suggesting 20% upside, the stock offers potential for patient investors despite near-term technical weakness.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
